Abstract
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is commonly used as a spice, food additive or dietary pigment. Accumulating evidence suggests that curcumin has several pharmacologic effects, including anti-inflammatory, anti-oxidant and anti-cancer activities. The molecular mechanisms underlying the targets of curcumin are diverse and involve combinations of multiple signaling pathways, including NF-κB and STAT3 signaling. Thus, curcumin is one of the most promising phytochemicals that target various cancers and inflammation-mediated diseases. Clinical trials have been ongoing or completed for various cancers, including breast, pancreatic and colorectal cancers, and multiple myeloma. In this review, the molecular mechanisms and the issue of bioavailability are mainly discussed.
Keywords: Bioavailability, cancer, curcumin, inflammation, NF-κB, rupture.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Curcumin Targets in Inflammation and Cancer
Volume: 15 Issue: 2
Author(s): Atsuko Deguchi
Affiliation:
Keywords: Bioavailability, cancer, curcumin, inflammation, NF-κB, rupture.
Abstract: Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is commonly used as a spice, food additive or dietary pigment. Accumulating evidence suggests that curcumin has several pharmacologic effects, including anti-inflammatory, anti-oxidant and anti-cancer activities. The molecular mechanisms underlying the targets of curcumin are diverse and involve combinations of multiple signaling pathways, including NF-κB and STAT3 signaling. Thus, curcumin is one of the most promising phytochemicals that target various cancers and inflammation-mediated diseases. Clinical trials have been ongoing or completed for various cancers, including breast, pancreatic and colorectal cancers, and multiple myeloma. In this review, the molecular mechanisms and the issue of bioavailability are mainly discussed.
Export Options
About this article
Cite this article as:
Deguchi Atsuko, Curcumin Targets in Inflammation and Cancer, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871530315666150316120458
DOI https://dx.doi.org/10.2174/1871530315666150316120458 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Study of Splicing Factor, Proline- and Glutamine-rich by Proteomic Techniques in Human Malignant and Nonmalignant Cell Lines
Protein & Peptide Letters Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology Modulation of Poly(A)-specific Ribonuclease (PARN): Current Knowledge and Perspectives
Current Medicinal Chemistry The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Current Cancer Drug Targets Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Current Molecular Medicine Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors
Current Drug Targets Chelating Agents Used for Plutonium and Uranium Removal in Radiation Emergency Medicine
Current Medicinal Chemistry Innovations in siRNA Research: A Technology Comes of Age
Recent Patents on Anti-Infective Drug Discovery Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis
Current Genomics Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
Current Pharmaceutical Design Polyoxometalates in Biomedicine: Update and Overview
Current Medicinal Chemistry Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design